Overview

• In a multicenter prospective study of 92 people with type 2 diabetes in Japan, higher baseline external eating scores were linked to greater 12‑month weight loss on GLP‑1 receptor agonists.
• Participants overall saw significant reductions in HbA1c, body weight and body fat after a year of treatment, with skeletal muscle mass largely preserved.
• Emotional eating decreased at three months but returned to baseline by 12 months, and authors suggest patients with strong emotional eating tendencies may benefit from added behavioral or psychological support.
• Dulaglutide and both oral and injectable semaglutide significantly lowered HbA1c and weight in this cohort, while liraglutide improved HbA1c without a significant weight change, likely reflecting small numbers.
• Authors caution that the findings come from a small observational study using self‑reported behaviors and unmeasured confounders, so they cannot establish causality or broad generalizability.